{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T17:28:33Z","timestamp":1771608513289,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070175"],"award-info":[{"award-number":["82070175"]}],"id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific program of Health Commission of Hunan Province","award":["20201179"],"award-info":[{"award-number":["20201179"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-024-01526-6","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T05:09:08Z","timestamp":1737090548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing staging in multiple myeloma using an m6A regulatory gene-pairing model"],"prefix":"10.1007","volume":"25","author":[{"given":"Yating","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongkai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"1526_CR1","first-page":"470","volume":"113","author":"C Gerecke","year":"2016","unstructured":"Gerecke C, et al. The diagnosis and treatment of multiple myeloma. Deutsch Arztebl Int. 2016;113:470\u20136.","journal-title":"Deutsch Arztebl Int"},{"key":"1526_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"1526_CR3","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u20139.","journal-title":"N Engl J Med"},{"key":"1526_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/864058","volume":"2014","author":"SM Prideaux","year":"2014","unstructured":"Prideaux SM, O\u2019Brien EC, Chevassut TJ. The genetic architecture of multiple myeloma. Adv Hematol. 2014;2014:1\u201316. https:\/\/doi.org\/10.1155\/2014\/864058.","journal-title":"Adv Hematol"},{"key":"1526_CR5","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"1526_CR6","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1526_CR7","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-16-0867","volume":"22","author":"R Szalat","year":"2016","unstructured":"Szalat R, Avet-Loiseau H, Munshi NC. Gene expression profiles in myeloma: ready for the real world? Clin Cancer Res. 2016;22:5434\u201342.","journal-title":"Clin Cancer Res"},{"key":"1526_CR8","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1038\/s41375-022-01662-6","volume":"36","author":"W Kong","year":"2022","unstructured":"Kong W, et al. An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia. Leukemia. 2022;36:2384\u201395.","journal-title":"Leukemia"},{"key":"1526_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-021-01066-6","volume":"14","author":"F Jiang","year":"2021","unstructured":"Jiang F, et al. HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. J Hematol Oncol. 2021;14:54.","journal-title":"J Hematol Oncol"},{"key":"1526_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s12967-022-03750-8","volume":"20","author":"C Jia","year":"2022","unstructured":"Jia C, et al. HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma. J Transl Med. 2022;20:537.","journal-title":"J Transl Med"},{"key":"1526_CR11","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.ymthe.2021.12.012","volume":"30","author":"A Xu","year":"2022","unstructured":"Xu A, et al. FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m(6)A-YTHDF2-dependent manner. Mol Ther. 2022;30:1104\u201318.","journal-title":"Mol Ther"},{"key":"1526_CR12","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1038\/s41388-021-01939-7","volume":"40","author":"S Song","year":"2021","unstructured":"Song S, et al. IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma. Oncogene. 2021;40:5393\u2013402.","journal-title":"Oncogene"},{"key":"1526_CR13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s41388-023-02675-w","volume":"42","author":"R Liu","year":"2023","unstructured":"Liu R, et al. N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1\/p21(cip1\/waf1)\/CDK2-Cyclin E1 axis-mediated cell cycle transition. Oncogene. 2023;42:1607\u201319.","journal-title":"Oncogene"},{"key":"1526_CR14","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/s41388-022-02191-3","volume":"41","author":"Z Hua","year":"2022","unstructured":"Hua Z, et al. YTHDF2 promotes multiple myeloma cell proliferation via STAT5A\/MAP2K2\/p-ERK axis. Oncogene. 2022;41:1482\u201391.","journal-title":"Oncogene"},{"key":"1526_CR15","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s10565-021-09690-1","volume":"39","author":"F Che","year":"2023","unstructured":"Che F, et al. METTL3 facilitates multiple myeloma tumorigenesis by enhancing YY1 stability and pri-microRNA-27 maturation in m(6)A-dependent manner. Cell Biol Toxicol. 2023;39:2033\u201350.","journal-title":"Cell Biol Toxicol"},{"key":"1526_CR16","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.7150\/ijbs.64943","volume":"18","author":"T Yu","year":"2022","unstructured":"Yu T, et al. ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m(6)A-demethylation of SAV1 mRNA and myeloma stem cell phenotype. Int J Biol Sci. 2022;18:2235\u201348.","journal-title":"Int J Biol Sci"},{"key":"1526_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.","journal-title":"Mol Cancer"},{"key":"1526_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","volume":"6","author":"X Jiang","year":"2021","unstructured":"Jiang X, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6:74.","journal-title":"Signal Transduct Target Ther"},{"key":"1526_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.molcel.2023.01.006","volume":"83","author":"E Sendinc","year":"2023","unstructured":"Sendinc E, Shi Y. RNA m6A methylation across the transcriptome. Mol Cell. 2023;83:428\u201341.","journal-title":"Mol Cell"},{"key":"1526_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12943-023-01782-2","volume":"22","author":"H Zhuang","year":"2023","unstructured":"Zhuang H, et al. The role of m6A methylation in therapy resistance in cancer. Mol Cancer. 2023;22:91.","journal-title":"Mol Cancer"},{"key":"1526_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27:491\u2013503.","journal-title":"Nat Med"},{"issue":"8","key":"1526_CR22","doi-asserted-by":"publisher","first-page":"104781","DOI":"10.1016\/j.isci.2022.104781","volume":"25","author":"T Masuda","year":"2022","unstructured":"Masuda T, Haji S, Nakashima Y, Tsuda M, Kimura D, Takamatsu A, Iwahashi N, Umakoshi H, Shiratsuchi M, Kikutake C, Suyama M, Ohkawa Y, Ogawa Y. Identification of a drug-response gene in multiple myeloma through longitudinal single-cell transcriptome sequencing. iScience. 2022;25(8):104781. https:\/\/doi.org\/10.1016\/j.isci.2022.104781.","journal-title":"iScience"},{"key":"1526_CR23","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, et al. Defining a cancer dependency map. Cell. 2017;170:564-576.e516.","journal-title":"Cell"},{"key":"1526_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16:385\u201395.","journal-title":"Stat Med"},{"key":"1526_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello SM, et al. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020;1:235\u201348.","journal-title":"Nat Cancer"},{"key":"1526_CR26","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1038\/s41375-021-01206-4","volume":"35","author":"HY Huang","year":"2021","unstructured":"Huang HY, et al. A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. Leukemia. 2021;35:3212\u201322.","journal-title":"Leukemia"},{"key":"1526_CR27","doi-asserted-by":"publisher","first-page":"731957","DOI":"10.3389\/fonc.2021.731957","volume":"11","author":"R Liu","year":"2021","unstructured":"Liu R, et al. Comprehensive analysis of m6A RNA methylation regulators in the prognosis and immune microenvironment of multiple myeloma. Front Oncol. 2021;11:731957.","journal-title":"Front Oncol"},{"key":"1526_CR28","doi-asserted-by":"publisher","first-page":"665173","DOI":"10.3389\/fgene.2021.665173","volume":"12","author":"W Wang","year":"2021","unstructured":"Wang W, et al. Identification and validation of a novel RNA-binding protein-related gene-based prognostic model for multiple myeloma. Front Genet. 2021;12:665173.","journal-title":"Front Genet"},{"key":"1526_CR29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/leu.2013.199","volume":"28","author":"BA Walker","year":"2014","unstructured":"Walker BA, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28:384\u201390.","journal-title":"Leukemia"},{"key":"1526_CR30","doi-asserted-by":"publisher","first-page":"100869","DOI":"10.1016\/j.blre.2021.100869","volume":"52","author":"H Mann","year":"2022","unstructured":"Mann H, Katiyar V, Varga C, Comenzo RL. Smoldering multiple myeloma - past, present, and future. Blood Rev. 2022;52:100869.","journal-title":"Blood Rev"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01526-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01526-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01526-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:44:50Z","timestamp":1764917090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01526-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1526"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01526-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"40"}}